AI won't fix medicine by speeding up drug pipelines, argues aging researcher Morgan Levine
DrMorganLevine · x · 2026-09-07
Aging researcher Dr. Morgan Levine argues the real bottleneck for AI in medicine isn't experiment pace or regulatory approval — it's that we haven't fundamentally rethought how we treat disease.
The dominant paradigm is still target → drug → clinical trial → approval. But most major chronic diseases, aging included, have no single cause or target, and cure attempts have largely failed. Even if AI massively accelerated this end-to-end pipeline, it wouldn't revolutionize human health.
Her case: AI should be used to confront biological complexity head-on and enable entirely new ways of treating disease, not just speed up the existing one.
More from AGI Musings
- New paper finds AI agents negotiate badly under uncertainty and break deals on purpose — xuanalogue · 2026-10-26
- NBER: Only 2.9% of US consumers pay for AI; retention as low as 20%, pricing power at risk — avicgoldfarb · 2026-10-26
- AI researchers guessed robots wouldn't outrun humans until 2034 — it already happened — ben_j_todd · 2026-10-26
- ESR on the Bugpocalypse: locking down frontier models only hands the game to Chinese open weights — colinmcnamara · 2026-10-26
- AI folks, stop saying "biology" when you mean drug development — KevinKaichuang · 2026-10-26
- Anthropic: junior tech hires fell from 27% to 9% as agent hours hit 6x employee hours — thione · 2026-10-26